We help pharma, biotech, and MedTech leaders connect R&D, regulatory, manufacturing and commercial on a single, compliant data foundation, so every team works from the same truth and patients see therapies sooner.
Life sciences leaders are navigating an unprecedented convergence of forces: accelerating science, tightening regulation, fragmenting channels, and rising patient expectations. The companies that win are the ones connecting their operating model end-to-end, not optimizing each silo in isolation.
FDA, EMA and emerging-market regulators are tightening expectations across submissions, labelling and post-market obligations. Staying ahead requires a continuous, auditable operating model, not project-by-project firefighting.
The cost-per-approval keeps climbing while pipelines grow more complex. Leaders need ways to accelerate discovery, run smarter trials and shorten the path from molecule to patient without compromising rigour.
Clinical, lab, manufacturing and commercial systems each hold a critical slice of truth. Without a unified, governed foundation, AI ambitions stall and every report becomes a reconciliation exercise.
Every batch, every deviation, every change has to stand up to audit. Connected MES, QMS and validated data flows turn GMP compliance from a paper exercise into a real-time operating discipline.
APIs, contract manufacturers, cold-chain partners and 3PLs span continents. One disruption can hold up release in dozens of markets, so visibility and orchestration have to be continuous, not periodic.
Serialisation, aggregation and track-and-trace mandates now extend from manufacturing to the patient. A single connected ledger of identity protects patients, brand, and regulatory standing.
We architect life sciences operations as a single continuous flow across research, regulatory, manufacturing, and post-market, sitting on a shared, validated foundation of product, study, supply and safety data.
R&D, clinical operations, biostatistics, lab informatics.
Regulatory affairs, labelling, RIMS, electronic submissions.
Manufacturing, quality, serialisation, cold-chain logistics.
Pharmacovigilance, post-market surveillance, RWE.
Four outcome-driven pillars that connect the work of every team, from discovery scientists to commercial leaders, on architectures that are validated, auditable, and ready for AI.
Bring trial design, study conduct, lab data, and real-world evidence into a unified clinical data fabric. Shorten study start-up, automate data cleaning, and feed insights back into protocol design with AI-assisted analytics on Databricks.
Operate global submissions, labelling, and adverse event intake as a single continuous capability. Automate case triage and signal detection so safety scientists spend time on judgement, not data entry, with full audit trail and 21 CFR Part 11 alignment.
Liberate batch and shop-floor data with edge connectivity, unify it with ERP and QMS, and make cold-chain and serialisation visibility continuous from API to patient. Predict deviations before they become release-blockers.
Move beyond rep-led, channel-siloed engagement. Connect HCP, payer, and patient interactions on a single profile, so medical affairs, market access, and patient services act on the same context, in compliance with privacy and promotional rules.
A snapshot of impact across recent pharma, MedTech and biotech engagements.
faster study start-up across a global Phase III portfolio
throughput on adverse-event case processing with AI triage
reduction in manual reconciliation across batch & release records
markets running serialisation & track-and-trace on one platform
We architect solutions using the world’s most powerful data, AI, and execution platforms to connect your enterprise from end to end.
Liberates data from PLCs and machines at the edge of the factory.
InspireXT's operating layer for autonomous, agentic operations.
Whether you are accelerating a launch, scaling pharmacovigilance, or rewiring your data foundation for AI, let’s map the next chapter of your life sciences transformation together.
